Jason Henry, MD
Critical Care Medicine · Augusta, GANPI 1235541673
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,045 of the $1,378 with a category attached, or 75.8%. 14 manufacturers reported payments, led by GSK at 26.0% of the total. 2025 is the largest year on record at $1,149, more than ten times the $98 reported in 2020.
Across 44 payments — averaging $31.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$358
- Cook Medical LLC$333
- AstraZeneca$133
- Sanofi$117
- Regeneron Healthcare Solutions, Inc.$103
- Intuitive Surgical$57
- plus $277 from 8 others
Across 13 payments — averaging $1905.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$25K
What the payments were for
- Travel & lodging$33324%
- Food & beverage$1,04576%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $358 |
| Cook Medical LLC | 1 | $333 |
| AstraZeneca | 6 | $133 |
| Sanofi | 4 | $117 |
| Regeneron Healthcare Solutions, Inc. | 2 | $103 |
| Intuitive Surgical | 2 | $57 |
| Viatris Specialty LLC | 2 | $50 |
| Grifols USA, LLC | 2 | $45 |
| Biogen | 1 | $40 |
| TG Therapeutics, Inc. | 1 | $34 |
| Johnson & Johnson | 1 | $31 |
| Merck | 1 | $29 |
| Insmed, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Blue Rhino$333
- NUCALA$125
How this compares
$1,378 in reported general payments places this provider in the 70th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $212,566 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $82,617 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $31,943 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $11,148 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $10,824 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $9,848 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,390 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,731 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,125 |
| Mycophenolate Mofetil | 26 | $2,055 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,145 |
| Ventolin HfaAlbuterol Sulfate | 13 | $728 |
| Montelukast Sodium | 24 | $395 |
| Azithromycin | 33 | $313 |
| Prednisone | 45 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $23 | $212,56616 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta | $358 | $114,437137 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $133 | $34,67431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Augusta
- Bruce FriedmanAugusta$629K
- Gabriel ThorntonAugusta$5K
- Anthony RamageAugusta$4K
- Charles OribaborAugusta$4K
- Amrita JariwalaAugusta$2K
- Salman FidahusseinLagrange$852K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.